Evidence map›Paper›PMID 20048702›Full record

ReviewCurrent opinion in HIV and AIDS2009

Fc receptor-mediated antiviral antibodies.

Donald N Forthal, Christiane Moog

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.

  1. Association ofFrontiers in immunology · 2025
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Comprehensive antibody profiling of mRNA vaccination in children.bioRxiv : the preprint server for biology · 2022
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Donald N ForthalDepartment of Medicine, Division of Infectious Diseases, University of California, Irvine School of Medicine, Irvine, California, USA. dnfortha@uci.edu
Christiane Moog
Institut de Virologie · FRUniversity of California, Irvine · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9M
The impact of antibody and pH on female-to-male SIV infectionR01AI102715 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N, MILLER, CHRISTOPHER JAMES · 2012 to 2015
$2.7M
Iron Starvation: A novel strategy for HIV and Chlamydia microbicidesR33AI079775 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N, PETERSON, ELLENA MARIE · 2011 to 2013
$1.2M
Protective immunity against HIV: the role of IgG subclass and glycosylationR21AI078477 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N · 2008 to 2009
$650k
Fcy Receptor Polymorphisms and Risk of HIV InfectionR21AI073147 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N · 2007 to 2008
$415k
Iron Starvation: A novel strategy for HIV and Chlamydia microbicidesR21AI079775 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N, PETERSON, ELLENA MARIE · 2009 to 2010
$415k
NIAID NIH HHS AI073147NIAID NIH HHS AI078477NIAID NIH HHS AI079775NIAID NIH HHS R01 AI102715NIAID NIH HHS R21 AI073147NIAID NIH HHS R21 AI078477NIAID NIH HHS R21 AI079775NIAID NIH HHS R33 AI079775NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854NIAID NIH HHS U19AI67854
6 · The paper itself

Abstract

purpose of reviewWe summarize current information on Fc receptor-mediated antiviral activities of antibodies. These activities include Fcgamma receptor-mediated inhibition and neutralization of HIV on antigen-presenting cells, antibody-dependent cellular cytotoxicity, and antibody-dependent cell-mediated virus inhibition (ADCVI). RECENT

findingsAn Fcgamma receptor-mediated mechanism that results in augmented neutralization and may render nonneutralizing antibodies inhibitory has been demonstrated in antigen-presenting cell. Antibody-dependent cellular cytotoxicity antibody activity correlates inversely with HIV disease progression in humans, and higher vaccine-induced antibody-dependent cellular cytotoxicity antibody responses are associated with lower acute simian immunodeficiency virus viremia levels in macaques. Following vaccination with rgp120, ADCVI antibody levels are higher among those with a lower rate of sexually acquired HIV infection. Nonneutralizing simian immunodeficiency virus immune serum that prevents infection of newborn macaques after oral challenge has potent ADCVI antibody activity. Abrogating the ability of the Fc segment of the broadly neutralizing mAb b12 to bind to Fcgamma receptors and to mediate ADCVI substantially reduces b12's protective effect in a simian/human immunodeficiency virus vaginal challenge model. SUMMARY: Fc-FcgammaR interactions play a critical role in the biological function of antibody and are likely to be instrumental in preventing or modulating lentiviral infection. Exploiting antibody responses that depend on Fc-FcgammaR interactions may help widen the breadth and increase the potency of vaccine-induced antibody. Although the importance of generating optimal Fab-antigen interactions cannot be overestimated, improving Fc-FcgammaR interactions through adjuvants or other strategies provides another option for improving HIV vaccines and immunotherapies.

Indexed as

AnimalsAntibodies, NeutralizingAntigen-Presenting CellsHIVHIV AntibodiesHIV InfectionsHumansMacacaReceptors, IgGSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusT-Lymphocytes, CytotoxicAntibodies, NeutralizingHIV AntibodiesReceptors, IgG

Identifiers

PMID20048702
PMCPMC2882066
OpenAlexW1980199406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.